Responsiveness and minimal clinically important difference for the EQ-5D in chronic rhinosinusitis

Area of Science:

• Health Outcomes Research
• Clinical Measurement
• Patient-Reported Outcomes

Background:

• The EuroQol 5-Dimension questionnaire (EQ-5D) is a validated tool for assessing general health-related quality of life (QOL).
• Chronic rhinosinusitis (CRS) significantly impacts patient QOL, necessitating reliable measurement tools.
• Understanding the responsiveness and minimal clinically important difference (MCID) of the EQ-5D is crucial for evaluating treatment efficacy in CRS.

Purpose of the Study:

• To determine the responsiveness of the EQ-5D health utility value (EQ-5D HUV) and visual analog scale (EQ-5D VAS) in patients with CRS.
• To establish the minimal clinically important difference (MCID) for both EQ-5D HUV and EQ-5D VAS in the context of CRS.

Main Methods:

• Prospective recruitment of 203 adults undergoing medical management for CRS.
• Measurement of general health-related QOL (EQ-5D HUV, EQ-5D VAS) and CRS-specific QOL (SNOT-22) at baseline and follow-up (2-12 months).
• Calculation of MCIDs using distribution-based, anchor-based, and receiver operator characteristic (ROC) curve methods, with patient-reported change in general health as the anchor.

Main Results:

• A correlation was observed between changes in SNOT-22 scores and changes in EQ-5D HUV and EQ-5D VAS.
• The calculated MCID for EQ-5D HUV was 0.04, and for EQ-5D VAS was 8.0.
• These MCIDs demonstrated approximately 40-50% sensitivity and 80% specificity in identifying patients with a noticeable improvement in general health.

Conclusions:

• The EQ-5D demonstrates good responsiveness to changes in CRS symptomatology.
• Proposed MCIDs for EQ-5D HUV (0.04) and EQ-5D VAS (8) in CRS patients are specific but lack sensitivity in detecting general health improvements.
• These findings aid in interpreting QOL changes in CRS patients using the EQ-5D.